Viropro Announces First Milestone Payment With Intas Biopharmaceuticals Limited
November 29, 2007 10:00 ET | Viropro, Inc.
MONTREAL, Nov. 29, 2007 (PRIME NEWSWIRE) -- Viropro Inc. (OTCBB:VPRO) is pleased to announce that its subsidiary Viropro International Inc. ("Viropro") has received payment for the first Milestone of...
Talon Therapeutics, Inc. Logo
Hana Biosciences to Present Data On Two Products and Debut Proprietary OPTISOME Platform At the American Society of Clinical Oncology Annual Meeting
May 25, 2007 12:46 ET | Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 25, 2007 (PRIME NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced that it will be presenting...
Viropro Inc. Issues a Business Update
March 13, 2007 11:18 ET | Viropro, Inc.
MONTREAL, March 13, 2007 (PRIME NEWSWIRE) -- As a result of ongoing initiatives developed last fall, Viropro Inc. (OTCBB:VPRO) ("Viropro", the "Company") issued today a second business update on its...
Millennium Biotechnologies Group Enters Into Asset Purchase Agreement With Aisling Capital to Exchange Nutraceutical Business for Equity in Newly Formed Company
October 25, 2006 11:31 ET | Millennium Biotechnologies Group
BASKING RIDGE, N.J., Oct. 25, 2006 (PRIMEZONE) -- Millennium Biotechnologies Group, Inc. (OTCBB:MBTG) announced today that it has entered into an Asset Purchase Agreement with RAC Nutrition...
Actelion and Roche Enter Into Autoimmune Disorder Collaboration
July 17, 2006 01:30 ET | Actelion Ltd.
Co-development for Actelion's Selective S1P1 Receptor Agonist in Multiple Indications With Co-promotion and Profit Share -- Actelion to Receive Upfront Payment of US$75 Million -- ...
Xenova Group plc - Scheme of Arrangement Confirmed by Court
August 30, 2005 10:21 ET | Xenova Group PLC
SLOUGH, U.K., Aug. 30, 2005 (PRIMEZONE) -- Xenova Group plc ("Xenova") (Nasdaq:XNVA)(LSE:XEN) is pleased to announce that the scheme of arrangement and the reduction of capital comprised within the...
Crucell NV Options to be Listed on Euronext.liffe Amsterdam
July 13, 2005 11:57 ET | Crucell N.V.
LEIDEN, Netherlands, July 13, 2005 (PRIMEZONE) -- Euronext.liffe today announced that options for Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) are to be listed on...
AFM Completes Investigation into Exercising of Options by Crucell Management
April 01, 2005 08:58 ET | Crucell N.V.
LEIDEN, Netherlands, April 1, 2005 (PRIMEZONE) -- The Netherlands Authority for the Financial Markets (AFM) has notified Crucell that its investigation into the exercise of options and the subsequent...
ImaRx Therapeutics, Inc. logo
ImaRx's Clot Dissolving Technology Being Presented at the AHA Conference
November 04, 2004 08:30 ET | ImaRx Therapeutics, Inc.
TUCSON, Ariz., Nov. 4, 2004 (PRIMEZONE) -- ImaRx Therapeutics, Inc. (www.imarx.com) is pleased to announce that Jeane M. Tsutsui, MD of the University of Nebraska Medical Center will be presenting...
Antisoma plc -- R&D Update: AS1404 Advancing to Phase II Trials; AS1405 Starts Clinical Trials in Brain Cancer
March 22, 2004 02:02 ET | Antisoma plc
LONDON, March 22, 2004 (PRIMEZONE) -- Antisoma plc (LSE:ASM), the biopharmaceutical company specialising in the development of novel anti-cancer drugs, will today hold an R&D update for analysts...